Market Research Logo

Global Mycoplasma Testing Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

Global Mycoplasma Testing Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

The global mycoplasma testing market is expected to grow with the CAGR of approximately 13.4% during the forecast period (2016-2023). The mycoplasma market is primarily driven due to various factors such as increasing funding for life science researches, increasing number of biotechnology & pharmaceutical firms, increasing demand for PCR based assays, increasing prevalence of mycoplasma infection across the globe and technological developments such as PCR technique. Commercial PCR tests having advantages in diagnosing M. pneumoniae infections as PCR is most reliable method for the detection of mycoplasma infection because it is not easy to culture mycoplasma on artificial media. Serology could be good and reliable screening tests for accurate diagnosis of M. pneumoniae. Numerous PCR methods based on 16SrDNA amplification comprise one- or two-step nested PCRs to identify mollicutes. Various methods is used for isolation of highly purified nucleic acids which is ideal for use in PCR and primarily used for detection of large number of samples. Increasing technological advancements enables to develop effectiveness and accuracy of testing and provides more accurate results. However, there are some factors restraining the market growth such as stringent government regulations and high cost associated with mycoplasma testing. Moreover, increasing healthcare spending in developing countries and growth in pharmaceutical outsourcing is creating opportunity for the mycoplasma testing market.

Geographically, North America is leading the mycoplasma testing market due to increasing focus on biopharmaceutical sector in the U.S. as well as better healthcare infrastructure for life science researches in the region. Furthermore, presence of major players such as Charles River Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Roche Diagnostics (Switzerland), Merck Millipore (U.S.), Lonza Group (Switzerland), Meridian Bioscience, Inc. (U.S.) etc. are creating opportunity for more technological developments in mycoplasma testing methods.

The global mycoplasma testing market is segmented on the basis of application, technology, end-user and product. The end-user segment is further classified into Cell banks, Academic research institutions, Contract research organizations, Pharmaceutical & Biotechnology companies and other end users. According to application, the mycoplasma testing market is further classified into cell line testing, virus testing, end of production cells and other applications. Cell line testing has led the largest revenue in 2016 due to increasing number of research activities undertaken for cell culture. Furthermore, increasing mycoplasma contamination in cell culture is also supporting to boost cell line testing application segment in the mycoplasma testing market. According to technology, the market is further segmented into PCR, DNA staining, Direct assay, Indirect assay, Enzymatic assay, Elisa and Microbial culture techniques. According to product segment, the market is further classified into Kits & Reagents, instruments and services.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2. MARKET OVERVIEW
2.1. GLOBAL MYCOPLASMA TESTING MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360-DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS
2.8.3. TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. INCREASING FUNDING FOR LIFE SCIENCE RESEARCH ACTIVITIES
3.1.2. INCREASING NUMBER OF BIOTECHNOLOGY & PHARMACEUTICAL FIRMS
3.1.3. INCREASING DEMAND FOR PCR BASED ASSAYS
3.1.4. TECHNOLOGICAL DEVELOPMENTS
3.1.5. INCREASING PREVALENCE OF MYCOPLASMA INFECTION ACROSS THE GLOBE
3.2. MARKET RESTRAINTS
3.2.1. STRINGENT GOVERNMENT REGULATIONS
3.2.2. HIGH COST ASSOCIATED WITH MYCOPLASMA TESTING
3.3. MARKET OPPORTUNITIES
3.3.1. INCREASING HEALTHCARE EXPENDITURE IN DEVELOPING COUNTRIES
3.3.2. GROWTH IN PHARMACEUTICAL OUTSOURCING.
3.4. MARKET CHALLENGES
3.4.1. LACK OF SKILLED PROFESSIONALS
4. MARKET SEGMENTATION
4.1. GLOBAL MYCOPLASMA TESTING MARKET BY APPLICATION
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. GLOBAL CELL LINE TESTING MARKET
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.2. GLOBAL VIRUS TESTING MARKET
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.2.4. KEY CONCLUSIONS
4.1.5.3. GLOBAL END OF PRODUCTION CELLS TESTING MARKET
4.1.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.3.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.3.4. KEY CONCLUSIONS
4.1.5.4. GLOBAL OTHER MYCOPLASMA TESTING APPLICATIONS MARKET
4.1.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.4.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.4.4. KEY CONCLUSIONS
4.2. GLOBAL MYCOPLASMA TESTING MARKET BY TECHNOLOGY
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. GLOBAL PCR MYCOPLASMA TESTING MARKET
4.2.5.1.1. APPLICATION
4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.5. KEY CONCLUSIONS
4.2.5.2. GLOBAL DNA STAINING MYCOPLASMA TESTING MARKET
4.2.5.2.1. APPLICATION
4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.5. KEY CONCLUSIONS
4.2.5.3. GLOBAL DIRECT ASSAY MYCOPLASMA TESTING MARKET
4.2.5.3.1. APPLICATION
4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.3.5. KEY CONCLUSIONS
4.2.5.4. GLOBAL INDIRECT ASSAY MYCOPLASMA TESTING MARKET
4.2.5.4.1. APPLICATION
4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.4.5. KEY CONCLUSIONS
4.2.5.5. GLOBAL ENZYMATIC METHODS MYCOPLASMA TESTING MARKET
4.2.5.5.1. APPLICATION
4.2.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.5.5. KEY CONCLUSIONS
4.2.5.6. GLOBAL ELISA MYCOPLASMA TESTING MARKET
4.2.5.6.1. APPLICATION
4.2.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.6.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.6.5. KEY CONCLUSIONS
4.2.5.7. GLOBAL MICROBIAL CULTURE TECHNIQUES MYCOPLASMA TESTING MARKET
4.2.5.7.1. APPLICATION
4.2.5.7.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.7.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.7.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.7.5. KEY CONCLUSIONS
4.3. GLOBAL MYCOPLASMA TESTING MARKET BY END-USER
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION
4.3.5.1. GLOBAL MYCOPLASMA TESTING MARKET IN CELL BANKS
4.3.5.1.1. APPLICATION
4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.1.5. KEY CONCLUSIONS
4.3.5.2. GLOBAL MYCOPLASMA TESTING MARKET IN ACADEMIC RESEARCH INSTITUTIONS
4.3.5.2.1. APPLICATION
4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.2.5. KEY CONCLUSIONS
4.3.5.3. GLOBAL MYCOPLASMA TESTING MARKET IN CONTRACT RESEARCH ORGANIZATIONS
4.3.5.3.1. APPLICATION
4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.3.5. KEY CONCLUSIONS
4.3.5.4. GLOBAL MYCOPLASMA TESTING MARKET IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
4.3.5.4.1. APPLICATION
4.3.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.4.5. KEY CONCLUSIONS
4.3.5.5. GLOBAL MYCOPLASMA TESTING MARKET IN OTHER END-USERS
4.3.5.5.1. APPLICATION
4.3.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.5.5. KEY CONCLUSIONS
4.4. GLOBAL MYCOPLASMA TESTING MARKET BY PRODUCT
4.4.1. MARKET DEFINITION AND SCOPE
4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.4.4. OPPORTUNITY MATRIX
4.4.5. MARKET SEGMENTATION
4.4.5.1. GLOBAL MYCOPLASMA TESTING KITS & REAGENTS MARKET
4.4.5.1.1. APPLICATION
4.4.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.4.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.1.5. KEY CONCLUSIONS
4.4.5.2. GLOBAL MYCOPLASMA TESTING INSTRUMENTS MARKET
4.4.5.2.1. APPLICATION
4.4.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.4.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.2.5. KEY CONCLUSIONS
4.4.5.3. GLOBAL MYCOPLASMA TESTING SERVICES MARKET
4.4.5.3.1. APPLICATION
4.4.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.4.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.4.5.3.5. KEY CONCLUSIONS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS AND ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
5.2. TOP 10 COMPANY ANALYSIS
6. GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL MYCOPLASMA TESTING MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
7. COMPANY PROFILES
7.1. ATCC COMPANY (U.S.)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2. BIOLOGICAL INDUSTRIES (U.S.)
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES
7.2.5. SCOT ANALYSIS
7.2.6. STRATEGIC ANALYSIS
7.3. BIONIQUE TESTING LABORATORIES, INC. (U.S.)
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES
7.3.5. SCOT ANALYSIS
7.3.6. STRATEGIC ANALYSIS
7.4. CHARLES RIVER LABORATORIES, INC. (U.S.)
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES
7.4.5. SCOT ANALYSIS
7.4.6. STRATEGIC ANALYSIS
7.5. EUROFINS SCIENTIFIC S.A. (U.S.)
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES
7.5.5. SCOT ANALYSIS
7.5.6. STRATEGIC ANALYSIS
7.6. GIBRALTAR LABORATORIES INC. (U.S.)
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES
7.6.5. SCOT ANALYSIS
7.6.6. STRATEGIC ANALYSIS
7.7. INVIVOGEN (U.S.)
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES
7.7.5. SCOT ANALYSIS
7.7.6. STRATEGIC ANALYSIS
7.8. LONZA GROUP (SWITZERLAND)
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES
7.8.5. SCOT ANALYSIS
7.8.6. STRATEGIC ANALYSIS
7.9. MERCK MILLIPORE (U.S.)
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES
7.9.5. SCOT ANALYSIS
7.9.6. STRATEGIC ANALYSIS
7.10. MERIDIAN BIOSCIENCE, INC. (U.S.)
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES
7.10.5. SCOT ANALYSIS
7.10.6. STRATEGIC ANALYSIS
7.11. MINERVA BIOLABS GMBH (GERMANY)
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES
7.11.5. SCOT ANALYSIS
7.11.6. STRATEGIC ANALYSIS
7.12. PROMOCELL GMBH (GERMANY)
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES
7.12.5. SCOT ANALYSIS
7.12.6. STRATEGIC ANALYSIS
7.13. R&D SYSTEMS, INC. (U.S.)
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES
7.13.5. SCOT ANALYSIS
7.13.6. STRATEGIC ANALYSIS
7.14. ROCHE DIAGNOSTICS (SWITZERLAND)
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES
7.14.5. SCOT ANALYSIS
7.14.6. STRATEGIC ANALYSIS
7.15. THERMO FISHER SCIENTIFIC INC. (U.S.)
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES
7.15.5. SCOT ANALYSIS
7.15.6. STRATEGIC ANALYSIS
LIST OF TABLES
GLOBAL MYCOPLASMA TESTING MARKET BY APPLICATION ($ MILLION)
GLOBAL CELL LINE TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL VIRUS TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL END OF PRODUCTION CELLS TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL OTHER MYCOPLASMA TESTING APPLICATIONS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET BY TECHNOLOGY ($ MILLION)
GLOBAL PCR MYCOPLASMA TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL DNA STAINING MYCOPLASMA TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL DIRECT ASSAY MYCOPLASMA TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL INDIRECT ASSAY MYCOPLASMA TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL ENZYMATIC METHODS MYCOPLASMA TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL ELISA MYCOPLASMA TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET BY END-USER ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET IN CELL BANKS BY GEOGRAPHY ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET IN ACADEMIC RESEARCH INSTITUTIONS BY GEOGRAPHY ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET IN CONTRACT RESEARCH ORGANIZATIONS BY GEOGRAPHY ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES BY GEOGRAPHY ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET BY PRODUCT ($ MILLION)
GLOBAL MYCOPLASMA TESTING KITS & REAGENTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL MYCOPLASMA TESTING INSTRUMENTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL MYCOPLASMA TESTING SERVICES MARKET BY GEOGRAPHY ($ MILLION)
NORTH AMERICA MYCOPLASMA TESTING MARKET ($ MILLION)
EUROPE MYCOPLASMA TESTING MARKET ($ MILLION)
ASIA PACIFIC MYCOPLASMA TESTING MARKET ($ MILLION)
REST OF THE WORLD MYCOPLASMA TESTING MARKET ($ MILLION)
LIST OF FIGURES
GLOBAL MYCOPLASMA TESTING MARKET ($ MILLION)
GLOBAL CELL LINE TESTING MARKET ($ MILLION)
GLOBAL VIRUS TESTING MARKET ($ MILLION)
GLOBAL END OF PRODUCTION CELLS TESTING MARKET ($ MILLION)
GLOBAL OTHER MYCOPLASMA TESTING APPLICATIONS MARKET ($ MILLION)
GLOBAL PCR MYCOPLASMA TESTING MARKET ($ MILLION)
GLOBAL DNA STAINING MYCOPLASMA TESTING MARKET ($ MILLION)
GLOBAL DIRECT ASSAY MYCOPLASMA TESTING MARKET ($ MILLION)
GLOBAL INDIRECT ASSAY MYCOPLASMA TESTING MARKET ($ MILLION)
GLOBAL ENZYMATIC METHODS MYCOPLASMA TESTING MARKET ($ MILLION)
GLOBAL ELISA MYCOPLASMA TESTING MARKET ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET IN CELL BANKS ($ MILLION)
GLOBAL ENZYMATIC METHODS MYCOPLASMA TESTING MARKET ($ MILLION)
GLOBAL ELISA MYCOPLASMA TESTING MARKET ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET IN CELL BANKS ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET IN ACADEMIC RESEARCH INSTITUTIONS ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET IN CONTRACT RESEARCH ORGANIZATIONS ($ MILLION)
GLOBAL MYCOPLASMA TESTING MARKET IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
GLOBAL MYCOPLASMA TESTING KITS & REAGENTS MARKET ($ MILLION)
GLOBAL MYCOPLASMA TESTING INSTRUMENTS MARKET ($ MILLION)
GLOBAL MYCOPLASMA TESTING SERVICES MARKET ($ MILLION)
UNITED STATES (U.S.) MYCOPLASMA TESTING MARKET ($ MILLION)
CANADA MYCOPLASMA TESTING MARKET ($ MILLION)
UNITED KINGDOM (UK) MYCOPLASMA TESTING MARKET ($ MILLION)
FRANCE MYCOPLASMA TESTING MARKET ($ MILLION)
GERMANY MYCOPLASMA TESTING MARKET ($ MILLION)
SPAIN MYCOPLASMA TESTING MARKET ($ MILLION)
ROE MYCOPLASMA TESTING MARKET ($ MILLION)
INDIA MYCOPLASMA TESTING MARKET ($ MILLION)
CHINA MYCOPLASMA TESTING MARKET ($ MILLION)
JAPAN MYCOPLASMA TESTING MARKET ($ MILLION)
AUSTRALIA MYCOPLASMA TESTING MARKET ($ MILLION)
ROAPAC MYCOPLASMA TESTING MARKET ($ MILLION)
LATIN AMERICA MYCOPLASMA TESTING MARKET ($ MILLION)
MENA MYCOPLASMA TESTING MARKET 2014-2023 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report